teclistamab
janssen,genmab
['majestec-1', 'teclistamab', 'imab ']
congress l #ash22 diana cortes-selva presents translational outcomes and data re: teclistamab from the phase i/ii majestec-1 study. baseline expression of bcma on bone marrow plasma cells is prevalent and highly variable in rrmm, but not associated with clinical responses 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma